tbuckley/cabot-search huggingface dataset:
Elwyn Tudor Jones
Authors: Jeremy Allgrove
Journal: BMJ (2020)

Elwyn Tudor Jones was a GP in rural north Wales for 30 years. During this time, while remaining what might be regarded as a traditional, “old-fashioned” practitioner, who knew his families and whose interests were always paramount, he oversaw the transition locally from the legacy of two singlehanded practices to a modern multipartnered dispensing practice housed in purpose built premises. He always maintained a progressive attitude, embraced modern technology, and was keen on training young doctors.

He was born in Bethesda, north Wales, in the heart of the Welsh slate mining industry, the second of three children (his older brother died in infancy) to William, who was a slate miner who had silicosis and was forced to retire early although he lived to the age of 73, and Olwen. Tudor was a staunch Welshman who spoke the language fluently (it was his first language) and conducted three quarters of his practice in Welsh. While doing his national service, he announced that he was taking the day off to celebrate St David’s Day, despite being told by his adjutant that this was not possible. He was a keen Welsh rugby supporter. He didn’t learn English until the age of …
Braf-V600 and C-Kit Mutation Analysis in Cytologycal Samples from Metastatic Melanoma
Authors: T. Labiano, M.D. Lozano, J.I. Echeveste, M. Montañana, M.F. Sanmamed, E. Castanon Alvarez, N. Gómez, A. Gurpide, M.A. Idoate, S. Martin Algarra
Journal: Annals of Oncology (2012)
Lung Cancer Harboring Her2 Mutation: Epidemiological Characteristics and Therapeutic Perspectives
Authors: J. Mazieres, S. Peters, A. Cortot, B. Besse, F. Barlesi, M. Beau-Faller, T. Urban, D. Moro-Sibilot, J. Milia, O. Gautschi
Journal: Annals of Oncology (2012)
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Authors: Anna-Maria Hoffmann-Vold, Toby M Maher, Edward E Philpot, Ali Ashrafzadeh, Rafic Barake, Simone Barsotti, Cosimo Bruni, Paolo Carducci, Patricia E Carreira, Ivan Castellví, Francesco Del Galdo, Jörg H W Distler, Ivan Foeldvari, Paolo Fraticelli, Peter M George, Bridget Griffiths, Alfredo Guillén-Del-Castillo, Abdul Monem Hamid, Rudolf Horváth, Michael Hughes, Michael Kreuter, Florentine Moazedi-Fuerst, Jacek Olas, Suman Paul, Cinzia Rotondo, Manuel Rubio-Rivas, Andrei Seferian, Michal Tomčík, Yurdagül Uzunhan, Ulrich A Walker, Ewa Więsik-Szewczyk, Oliver Distler
Journal: The Lancet Rheumatology (2020)
HIV persists throughout deep tissues with repopulation from multiple anatomical sources
Authors: Antoine Chaillon, Sara Gianella, Simon Dellicour, Stephen A. Rawlings, Timothy E. Schlub, Michelli Faria De Oliveira, Caroline Ignacio, Magali Porrachia, Bram Vrancken, Davey M. Smith
Journal: Journal of Clinical Investigation (2020)

BACKGROUND. Understanding HIV dynamics across the human body is important for cure efforts. This goal has been hampered by technical difficulties and the challenge of obtaining fresh tissues.
FSTL-1: A New Player in the Prevention of Emphysema
Authors: Ross Vlahos
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

lung inflation affect the degree of airway closure, impacting relationships between supine TAC and upright residual volume/TLC in COPD (2) and asthma (5).Although it is possible for lung models to estimate the posture-dependent effect (15), many physiological tests can be performed in both the upright and supine positions.A practical challenge for future HRCT studies is to reduce radiation exposure, enabling dynamic CT images to investigate the intermittent nature of airway closure in asthma, or the expansion dynamics of the thinned airway walls in COPD (2) and thickened airway walls in asthma (5).On both the image and lung function sides, we owe it to patients with lung disease to make every possible effort to extract as much structural information from the images we have, and to make the lung models that can help us interpret the structure-function link as realistic as possible.This is where morphometric and ventilation data obtained from the same patients (5) can be very helpful.
Diagnostic Medical Mycology.
Journal: Annals of Internal Medicine (1965)

This book was provide well defined summary of scientific information covering most parts of theoretical and practical areas of medical mycology. The book was oriented mainly for students of medical laboratory sciences and medicine, but the book also useful for all students of other medical fields. The book was arranged in three sections, section one deals with general characteristic of fungi from cell structure and morphology until uses of fungi for industrial purposes, with little focusing in laboratory diagnosis. Section two contains notes on some of most common and famous fungi whereas section three contains common mycosis. To avoid duplication of information in section three, the species that cause mycosis are detailed when the fungi of section two are just mentioned. Glossary unit contains some words that don’t included in the text, and this to evade entrance of irrelevant definitions to keep the information intact.
Prospective Study of Switch from Oral Medicine of Tramadolto Fentanyl Sticking Medicine in Thoracic Malignancy with the Pain
Authors: M. Tamiya, T. Hirashima, M. Kobayashi, S. Morita, O. Morimura, T. Shiroyama, K. Okafuji, Y. Matsuura, N. Morishita, H. Suzuki, K. Iwata, N. Ryota, H. Hino, N. Okamoto, I. Kawase
Journal: Annals of Oncology (2012)
Safety and Efficacy of 5FU–LV (FL Therapy) as First-Line Chemotherapy in Patients of Advanced Gastric Cancer with Severe Ascites or Inadequate Oral Intake
Authors: H. Sawai, H. Yasui, H. Taniguchi, T. Tsushima, A. Todaka, T. Yokota, N. Machida, K. Yamazaki, A. Fukutomi, Y. Onozawa
Journal: Annals of Oncology (2012)
Biweekly Carboplatin and Paclitaxel as First-Line Therapy for Elderly Advanced Non-Small Cell Lung Cancer Patients (Phase II Study)
Authors: I. Kota, K. Soejima, K. Naoki, H. Yasuda, H. Terai, A. Daisuke, K. Ohgino, S. Yoda, S. Ikemura, T. Betsuyaku
Journal: Annals of Oncology (2012)
Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer
Authors: X. Pivot, G. Romieu, H. Bonnefoi, J.-Y. Pierga, P. Kerbrat, J.-P. Guastalla, A. Lortholary, M. Espié, P. Fumoleau, D. Serin, J.-P. Jacquin, C. Jouannaud, M. Rios, S. Abadie-Lacourtoisie, N. Tubiana-Mathieu, L. Cany, S. Catala, D. Khayat, I. Pauporte, A. Kramar
Journal: Annals of Oncology (2012)
Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation
Authors: Premanand Tiwari, Kathryn L. Colborn, Derek E. Smith, Fuyong Xing, Debashis Ghosh, Michael A. Rosenberg
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its early detection could lead to significant improvements in outcomes through the appropriate prescription of anticoagulation medication. Although a variety of methods exist for screening for AF, a targeted approach, which requires an efficient method for identifying patients at risk, would be preferred. <h3>Objective</h3> To examine machine learning approaches applied to electronic health record data that have been harmonized to the Observational Medical Outcomes Partnership Common Data Model for identifying risk of AF. <h3>Design, Setting, and Participants</h3> This diagnostic study used data from 2 252 219 individuals cared for in the UCHealth hospital system, which comprises 3 large hospitals in Colorado, from January 1, 2011, to October 1, 2018. Initial analysis was performed in December 2018; follow-up analysis was performed in July 2019. <h3>Exposures</h3> All Observational Medical Outcomes Partnership Common Data Model–harmonized electronic health record features, including diagnoses, procedures, medications, age, and sex. <h3>Main Outcomes and Measures</h3> Classification of incident AF in designated 6-month intervals, adjudicated retrospectively, based on area under the receiver operating characteristic curve and F1 statistic. <h3>Results</h3> Of 2 252 219 individuals (1 225 533 [54.4%] women; mean [SD] age, 42.9 [22.3] years), 28 036 (1.2%) developed incident AF during a designated 6-month interval. The machine learning model that used the 200 most common electronic health record features, including age and sex, and random oversampling with a single-layer, fully connected neural network provided the optimal prediction of 6-month incident AF, with an area under the receiver operating characteristic curve of 0.800 and an F1 score of 0.110. This model performed only slightly better than a more basic logistic regression model composed of known clinical risk factors for AF, which had an area under the receiver operating characteristic curve of 0.794 and an F1 score of 0.079. <h3>Conclusions and Relevance</h3> Machine learning approaches to electronic health record data offer a promising method for improving risk prediction for incident AF, but more work is needed to show improvement beyond standard risk factors.
P-0229 Characteristics and Outecome of Young Patients with Colorectal Cancer
Authors: Karima Oualla, Fatima Zahra El M'rabet, Lamiae Amaadour, Hafida Benhammane, Nezar Bouyahia, Samia Arifi, Nawfel Mellas, Omar El Mesbahi
Journal: Annals of Oncology (2012)
Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy?
Authors: Maximilian L. Müller, Javed Butler, Bettina Heidecker
Journal: European Journal of Heart Failure (2020)

Transthyretin amyloidosis (ATTR) is a rare, yet underdiagnosed disease characterized by progressive impairment of neurologic and cardiac function due to deposition of misfolded transthyretin. Despite great efforts, such as the introduction of orthotopic liver transplant, the devastating prognosis for both variant and wild‐type ATTR patients remained unchanged over the last decades, mainly due to a lack of specific therapies. Fortunately, recent years saw the introduction of promising targeted therapies, which aim to interfere with the deposition of misfolded transthyretin (TTR) at various stages of the cascade underlying ATTR progression. These include TTR tetramer stabilizers (tafamidis, diflunisal, epigallocatechin‐3‐gallate), TTR silencers (inotersen, patisiran) and fibril disruptors (monoclonal antibodies, doxycycline and tauroursodeoxycholic acid). In the context of this review we explain their mechanisms of action, analyse their efficacy on neurologic and cardiac function based on all clinical trials conducted to date and discuss their clinical applicability. Eventually suggestions for future clinical research into the field are provided.
Genetic risk and atrial fibrillation in patients with heart failure
Authors: Mariëlle Kloosterman, Bernadet T. Santema, Carolina Roselli, Christopher P. Nelson, Andrea Koekemoer, Simon. P.R. Romaine, Isabelle C. Van Gelder, Carolyn S.P. Lam, Vicente A. Artola, Chim C. Lang, Leon L. Ng, Marco Metra, Stefan Anker, Gerasimos Filippatos, Kenneth Dickstein, Piotr Ponikowski, Pim van der Harst, Peter van der Meer, Dirk J. van Veldhuisen, Emelia J. Benjamin, Adriaan A. Voors, Nilesh J. Samani, Michiel Rienstra
Journal: European Journal of Heart Failure (2020)

To study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all-cause mortality in patients with heart failure.An AF genetic risk score was calculated in 3759 European ancestry individuals (1783 with sinus rhythm, 1976 with AF) from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) by summing 97 single nucleotide polymorphism (SNP) alleles (ranging from 0-2) weighted by the natural logarithm of the relative SNP risk from the latest AF genome-wide association study. Further, we assessed AF risk variance explained by additive SNP variation, and performance of clinical or genetic risk factors, and the combination in classifying AF prevalence. AF was classified as AF or atrial flutter (AFL) at baseline electrocardiogram and/or a history of AF or AFL. The genetic risk score was associated with AF after multivariable adjustment. Odds ratio for AF prevalence per 1-unit increase genetic risk score was 2.12 (95% confidence interval 1.84-2.45, P = 2.15 × 10-24 ) in the total cohort, 2.08 (1.72-2.50, P = 1.30 × 10-14 ) in heart failure with reduced ejection fraction (HFrEF) and 2.02 (1.37-2.99, P = 4.37 × 10-4 ) in heart failure with preserved ejection fraction (HFpEF). AF-associated loci explained 22.9% of overall AF SNP heritability. Addition of the genetic risk score to clinical risk factors increased the C-index by 2.2% to 0.721.The AF genetic risk score was associated with increased AF prevalence in HFrEF and HFpEF. Genetic variation accounted for 22.9% of overall AF SNP heritability. Addition of genetic risk to clinical risk improved model performance in classifying AF prevalence.
Neoadjuvant Multidisciplinary Phase II Study (BRANCH) of an Early Bevacizumab Schedule Plus Chemo-Radiation Therapy in Rectal Cancer: Efficacy, Safety, and Biomarkers
Authors: A. Avallone, E. Di Gennaro, L. Aloj, P. Delrio, B. Pecori, F. Tatangelo, A. Petrillo, V.R. Iaffaioli, S. Lastoria, A. Budillon
Journal: Annals of Oncology (2012)
Body Mass Index and Impaired Fasting Blood Glucose as Predictive Factors of Efficacy in Cetuximab-Based Colorectal Cancer Treatment
Authors: F.M. Guida, F. Pantano, E. Vasile, M. Rodriguez Garrote, E. Grande, N. Silvestris, B. Vincenzi, D. Santini, A. Falcone, G. Tonini
Journal: Annals of Oncology (2012)
Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure
Authors: Hillary S. Hayden, Alexander Eng, Christopher E. Pope, Mitchell J. Brittnacher, Anh T. Vo, Eli J. Weiss, Kyle R. Hager, Bryan D. Martin, Daniel H. Leung, Sonya L. Heltshe, Elhanan Borenstein, Samuel I. Miller, Lucas R. Hoffman
Journal: Nature Medicine (2020)
Generalism for specialists: a medical reformation
Authors: Kamran Abbasi
Journal: BMJ (2020)

Reform of medicine is urgent and necessary. Increasingly, patients have two or more conditions at the same time, but clinicians are devoted to one disease, body part, or organ. Training, clinical teams, guidelines, and research are focused on an isolated component. An intellectual shift is required to think of multimorbidity as predictable clusters instead of a random assortment of individual parts. And that sea change is the revival of generalism, even for specialists.

It is possible and desirable to be both a specialist …
Coexistence of Positive MET Fish Status with EGFR Mutations Signifies Poor Prognosis in Primary Lung Adenocarcinoma
Authors: N. Kobayashi, N. Aragane, T. Nakamura, K. Komiya, H. Umeguchi, S. Hayashi, E. Sueoka, S. Kimura
Journal: Annals of Oncology (2012)
Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/BEV) In Patients with Metastatic Colorectal Cancer -Updated Analysis-. Hokkaido Gastrointestinal Cancer Study Group (HGCSG) Trial
Authors: K. Hatanaka, S. Yuki, T. Miyagishima, T. Kato, M. Nakamura, M. Kudo, M. Tateyama, M. Asaka, Y. Sakata, Y. Komatsu
Journal: Annals of Oncology (2012)
Phase IB Dose-Escalation Study of the Akt Inhibitor Gdc-0068 with Docetaxel (D) or Modified Folfox6 (F) in Patients (PTS) with Advanced Solid Tumors
Authors: J. Bendell, D. Roda, J. Mateo, A. Hollebecque, L. De Mattos-Arruda, R. Meng, S. Isakoff, L.R. Molife, J. Tabernero, A. Cervantes Ruiperez
Journal: Annals of Oncology (2012)
The Treatment Options of Recurred Brain Metastasis after Prophylactic Cranial Irradiation in Patients with Small-Cell Lung Cancer
Authors: J.H. Ji, B. Han, J.M. Sun, D.H. Lee, J.-I. Lee, Y.C. Ahn, J.S. Ahn, S.W. Kim, M.-J. Ahn, K. Park
Journal: Annals of Oncology (2012)
Biosimilar Filgrastim Initiation in Patients Enrolled in the Monitor G-CSF Observational Study Relative to EORTC Guidelines
Authors: M.S. Aapro, P. Gascon, H. Ludwig, C. Bokemeyer, M. Boccadoro, M. Turner, M. Muenzberg, K. Denhaerynck, I. Abraham, K. Macdonald
Journal: Annals of Oncology (2012)
O-0009 Second Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)
Authors: Camillo Porta, Ivan Borbath, Lorenza Rimassa, Bruno Daniele, Stefania Salvagni, Jean Luc Van Laethem, Hans Van Vlieberghe, Joerg Trojan, Frank Kolligs, Antonio Gasbarrini, Alan Weiss, Monica Lencioni, Giovanni Abbadessa, Brian Schwartz, Armando Santoro
Journal: Annals of Oncology (2012)
ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 Appropriate Use Criteria for Multimodality Imaging During the Follow-Up Care of Patients With Congenital Heart Disease
Authors: Ritu Sachdeva, Anne Marie Valente, Aimee K. Armstrong, Stephen C. Cook, B. Kelly Han, Leo Lopez, George K. Lui, Sarah S. Pickard, Andrew J. Powell, Nicole M. Bhave, Ritu Sachdeva, Anne Marie Valente, Sarah S. Pickard, Jeanne M. Baffa, Puja Banka, Scott B. Cohen, Julie S. Glickstein, Joshua P. Kanter, Ronald J. Kanter, Yuli Y. Kim, Alaina K. Kipps, Larry A. Latson, Jeannette P. Lin, David A. Parra, Fred H. Rodriguez, Elizabeth V. Saarel, Shubhika Srivastava, Elizabeth A. Stephenson, Karen K. Stout, Ali N. Zaidi
Journal: Journal of the American College of Cardiology (2020)
Association of Maternal Psychological Distress With In Utero Brain Development in Fetuses With Congenital Heart Disease
Authors: Yao Wu, Kushal Kapse, Marni Jacobs, Nickie Niforatos-Andescavage, Mary T. Donofrio, Anita Krishnan, Gilbert Vezina, David Wessel, Adré du Plessis, Catherine Limperopoulos
Journal: JAMA Pediatrics (2020)

Prenatal maternal psychological distress can result in detrimental mother and child outcomes. Maternal stress increases with receipt of a prenatal diagnosis of fetal congenital heart disease (CHD); however, the association between maternal stress and the developing brain in fetuses with CHD is unknown.To determine the association of maternal psychological distress with brain development in fetuses with CHD.This longitudinal, prospective, case-control study consecutively recruited 48 pregnant women carrying fetuses with CHD and 92 healthy volunteers with low-risk pregnancies from the Children's National Health System between January 2016 and September 2018. Data were analyzed between January 2016 and June 2019.Fetal CHD and maternal stress, anxiety, and depression.Maternal stress, anxiety, and depression were measured using the Perceived Stress Scale, Spielberger State-Trait Anxiety Inventory, and Edinburgh Postnatal Depression Scale, respectively. Volumes of fetal total brain, cerebrum, left and right hippocampus, cerebellum, and brainstem were determined from 3-dimensionally reconstructed T2-weighted magnetic resonance imaging (MRI) scans.This study included 223 MRI scans from 140 fetuses (74 MRIs from 48 fetuses with CHD and 149 MRIs from 92 healthy fetuses) between 21 and 40 weeks' gestation. Among 48 women carrying fetuses with CHD, 31 (65%) tested positive for stress, 21 (44%) for anxiety, and 14 (29%) for depression. Among 92 pregnant women carrying healthy fetuses, 25 (27%) tested positive for stress, 24 (26%) for anxiety, and 8 (9%) for depression. Depression scores were higher among 17 women carrying fetuses with single-ventricle CHD vs 31 women carrying fetuses with 2-ventricle CHD (3.8; 95% CI, 0.3 to 7.3). Maternal stress and anxiety were associated with smaller left hippocampal (stress: -0.003 cm3; 95% CI, -0.005 to -0.001 cm3), right hippocampal (stress: -0.004; 95% CI, -0.007 to -0.002; trait anxiety: -0.003; 95% CI, -0.005 to -0.001), and cerebellar (stress: -0.06; 95% CI, -0.09 to -0.02) volumes only among women with fetal CHD. Impaired hippocampal regions were noted in the medial aspect of left hippocampal head and inferior aspect of right hippocampal head and body. Impaired cerebellar regions were noted in the anterior superior aspect of vermal and paravermal regions and the left cerebellar lobe.These findings suggested that psychological distress among women carrying fetuses with CHD is prevalent and is associated with impaired fetal cerebellar and hippocampal development. These data underscore the importance of universal screening for maternal psychological distress, integrated prenatal mental health support, and targeted early cognitive-behavioral interventions given that stress is a potentially modifiable risk factor in this high-risk population.
What is the clinical value of mHealth for patients?
Authors: Simon P. Rowland, J. Edward Fitzgerald, Thomas Holme, John Powell, Alison McGregor
Journal: npj Digital Medicine (2020)

Abstract Despite growing interest from both patients and healthcare providers, there is little clinical guidance on how mobile apps should be utilized to add value to patient care. We categorize apps according to their functionality (e.g. preventative behavior change, digital self-management of a specific condition, diagnostic) and discuss evidence for effectiveness from published systematic reviews and meta-analyses and the relevance to patient care. We discuss the limitations of the current literature describing clinical outcomes from mHealth apps, what FDA clearance means now (510(k)/de novo FDA clearance) and in the future. We discuss data security and privacy as a major concern for patients when using mHealth apps. Patients are often not involved in the development of mobile health guidelines, and professionals’ views regarding high-quality health apps may not reflect patients’ views. We discuss efforts to develop guidelines for the development of safe and effective mHealth apps in the US and elsewhere and the role of independent app reviews sites in identifying mHealth apps for patient care. There are only a small number of clinical scenarios where published evidence suggests that mHealth apps may improve patient outcomes.
Testing Hypothermic Preservation for Trauma Patients
Authors: Jennifer Abbasi
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
It is time to further expand research in tailoring self-management of COPD exacerbations!
Authors: Anke Lenferink, Job van der Palen, Paul D.L.P.M. van der Valk, Morton G. Burt, Peter A. Frith, Marjolein G.J. Brusse-Keizer, Tanja W. Effing
Journal: European Respiratory Journal (2020)

<b>Tailoring self-treatment by adding exacerbation phenotyping could be explored. Evidence on phenotyping effects, an accurate tool to identify eosinophilic exacerbations, and a validated cut-off point are needed before eosinophils can be used in practice.</b>http://bit.ly/2L4b6SR